US 11,912,995 B2
CTLA-4 aptamer conjugates
Hua Yu, Glendora, CA (US); Andreas Herrmann, La Jolla, CA (US); Marcin Tomasz Kortylewski, Monrovia, CA (US); and Piotr Marek Swiderski, San Dimas, CA (US)
Assigned to City of Hope, Duarte, CA (US)
Filed by City of Hope, Duarte, CA (US)
Filed on Oct. 25, 2021, as Appl. No. 17/452,172.
Application 17/452,172 is a continuation of application No. 16/892,995, filed on Jun. 4, 2020, granted, now 11,186,840.
Application 16/892,995 is a continuation of application No. 14/602,182, filed on Jan. 21, 2015, granted, now 10,711,272, issued on Jul. 14, 2020.
Claims priority of provisional application 61/929,832, filed on Jan. 21, 2014.
Prior Publication US 2022/0145299 A1, May 12, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07H 21/04 (2006.01); C12N 15/113 (2010.01); A61K 31/713 (2006.01); C12N 15/115 (2010.01); C12N 15/11 (2006.01); A61K 45/06 (2006.01); A61K 47/54 (2017.01)
CPC C12N 15/113 (2013.01) [A61K 31/713 (2013.01); A61K 45/06 (2013.01); A61K 47/549 (2017.08); C12N 15/111 (2013.01); C12N 15/115 (2013.01); C12N 15/1138 (2013.01); C12N 2310/11 (2013.01); C12N 2310/12 (2013.01); C12N 2310/13 (2013.01); C12N 2310/14 (2013.01); C12N 2310/16 (2013.01); C12N 2310/3519 (2013.01); C12N 2320/30 (2013.01); C12N 2320/32 (2013.01)] 17 Claims
 
1. A nucleic acid compound comprising a monomeric CTLA-4 aptamer nucleic acid conjugated to a Signal Transducer and Activator of Transcription 3 (STAT3) antisense nucleic acid.